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TO THE EDITOR
Tetracyclines are commonly used for
the treatment of acne and rosacea. In
addition to their antibacterial properties,
tetracyclines are increasingly being
studied for other properties, such as their
anti-inflammatory properties (Jackson
et al., 1999; Meier, 2000; Sho et al.,
2004; Griffin et al., 2005; Tessone et al.,
2006; Hackmann et al., 2008; Romero-
Perez et al., 2008; Griffin et al., 2010).
One can hypothesize that these qualities
may have secondary benefits and a
protective effect on other organ systems.
We sought to test the hypothesis that
tetracyclines used in acne and rosacea
patients may have secondary benefits on
the cardiovascular system, specifically,
a decreased odds ratio of developing
vascular diseases.
After approval by the Institutional
Review Board at the Miami Veterans
Affairs Health System, we used the
electronic medical records from the
veterans integrated service network-8
(which includes the Veterans Affairs
medical centers of Bay Pines, Miami,
West Palm Beach, Tampa, North Flor-
ida/South Georgia, and San Juan) to
perform a retrospective observational
cohort study and identify patients with
the diagnosis of acne or rosacea using
the International Classifications of Dis-
eases, Ninth Revision, Clinical Modifi-
cation (ICD-9) codes during the period
of 1 July 2004 through 30 June 2010,
allowing for at least 18 months of
follow-up. We excluded any patient
who had been diagnosed with vascular
disease before prescription of a tetracy-
cline, or before the diagnosis of
acne/rosacea. Demographic, clinic, and
pharmacy data were extracted. Vascular
disease was defined and identified using
the ICD-9 codes for cardiovascular
disease, cerebrovascular disease, ather-
osclerosis, and aortic aneurysm with or
without rupture/dissection.
In a multiple logistic regression model,
age, sex, and comorbidities (see Table 1)
were included as covariates. The
Hosmer–Lemeshow test was performed
to assess goodness-of-fit. P-values were
reported as two sided. Statistical analyses
were performed using SAS software (Ver-
sion 9.2, SAS Institute, Cary, NC).
In total, 13,847 patients matched our
inclusion and exclusion criteria (Figure 1).
Patients were further subdivided—to
those with prior treatment with a tetra-
cycline, and those without tetracycline
treatment (control). Demographics can
be found in Table 1. There were similar
race profiles between control and
treatment groups within both the acne
and rosacea sets (data not shown).
Similar rates of comorbidities were
found between study and control groups
(Table 1).
Of those rosacea patients who were
treated with a tetracycline, 12.56%
patients developed a new diagnosis of
vascular disease compared with 17.15%
of the control group. Overall, rosacea
patients who were prescribed a tetracy-
cline had an odds ratio of 0.69 for the
development of vascular disease when
compared with those not prescribed a
tetracycline (odds ratio 0.69 in the uni-
variate model, 95% confidence interval
(CI) 0.61–0.79, Po0.05; odds ratio
0.78 in the multivariate model, 95% CI
0.68–0.89, Po0.05) (Table 1).
Acne patients showed an odds ratio of
0.79 (95% CI 0.62–1.02) in a univariate
model; however, the results were not
statistically significant, and did not per-
sist with the multivariate model.
The effect of treatment duration
(o3 months, 3–12 months, 412 months
of daily dosing with a tetracycline) was
explored; however, the group sizes were
too small to make meaningful conclu-
sions (data not shown). Cumulative dose
effect was not explored, nor was daily
dosage.
A statistically significant decrease was
found in the development of new aortic
aneurysms in rosacea patients treated
with doxycycline (P¼ 0.007) (Table 1),
although the number of cases was quite
small. Other vascular diagnoses were
not analyzed individually.
We found a potential association
between the administration of tetracy-
clines and a decreased odds ratio for
the development of vascular disease in
veterans with rosacea. This study further
contributes to the body of literature sup-
porting an association between chronic
low-grade inflammation and cardiovas-
cular disease (Prodanowich et al., 2005;
Wang et al., 2012). One can conjecture
that the stabilization or inhibition of
matrix metalloproteinases by tetracyc-
lines has a beneficial effect on the
vascular wall and/or calcifications in
arteries.
We did not detect any benefit of
tetracyclines in acne patients, possibly
due to the inherent demographics of
acne patients. The average age of our
acne patients may be too young to
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detect incipient or future vascular dis-
ease with our degree of follow-up.
Of note, the use of tetracyclines has
garnered some disturbing attention in the
last several years including increased
risk of inflammatory bowel disease
(Margolis et al., 2010). A discussion of
these risks is beyond the scope of this
article, but is important to the under-
standing of tetracyclines (Margolis et al.,
2007; Sergentanis et al., 2010). We
contend that researchers may also need
to explore the potential secondary
benefits of tetracyclines.
Our study is a large review, however,
due to its retrospective nature, care
should be taken when interpreting our
results. It would be premature to assume
that there is a strong association
between administration of tetracyclines
and the incidence of vascular disease.
Further large-scale studies with rigorous
attention to potential confounders are
needed. Time from tetracycline exposure
to cardiovascular disease was not fac-
tored into our analysis, nor was age-
by-exposure interaction. By excluding
previous vascular disease before tetracy-
cline use, we may have selected a heal-
thier group. However, as our primary
Screened for eligibility
(n= 21,132) Excluded (n= 7,285) (34.4% of those
screened)
Diagnosis of vascular disease before
diagnosis of rosacea/acne
Diagnosed with vascular disease before
prescribed a tetracycline
Patients included (n= 13,847)
(65.6% of patients screened)
Rosacea n= 8,923 (64.4%)
Tetracycline treatment
N = 2,883 (32.3%)
No tetracycline treatment
N = 6,040 (67.7%)
Tetracycline treatment
N = 2,161 (43.9%)
No tetracycline treatment
N = 2,763 (56.1%)
Vascular disease (VD)
VD
N = 362
(12.56%)
No VD
N = 2,521
(87.44%)
VD
N = 1,036
(17.15%)
No VD
N = 5,004
(82.84%)
VD
N = 108
(5.0%)
No VD
N = 2,053
(95.0%)
VD
N = 172
(6.23%)
No VD
N = 2,691
(93.77%)
Acne n= 4,924 (35.6%)
Figure 1. Flow diagram of study design. .
Table 1. Demographics, comorbidities, and outcomes
Demographics and comorbidities
Rosacea Acne
Overall Control Treatment Overall Control Treatment
n¼ 8,923 n¼6,040 n¼2,883 n¼ 4,924 n¼2,763 n¼2,161
Age (year), mean (SD) 66.86 (12.03) 67.78 (12.05) 64.95 (11.76) 44.82 (16.42) 46.49 (17.35) 42.70 (14.88)
Sex (male), n (%) 8,342 (93.49) 5,680 (94.04) 2,662 (92.33) 3,286 (66.73) 1,834 (66.38) 1,452 (67.19)
Diabetes, n (%) 761 (8.52) 490 (8.11) 271 (9.40) 245 (4.97) 137 (4.96) 108 (5.00)
Dyslipidemia, n (%) 1,950 (21.85) 1,327 (21.97) 623 (21.61) 895 (18.18) 509 (18.42) 386 (17.86)
Hypertention, n (%) 1,637 (18.34) 1,073 (17.76) 564 (19.56) 681 (13.83) 409 (14.80) 272 (12.59)
Outcomes
Vascular Disease, n (%) 1,398 (15.67) 1,036 (17.15) 362 (12.56) 280 (5.69) 172 (6.23) 108 (5.00)
Aortic aneurysm, n (%) 189 (2.12) 145 (2.40) 44 (1.53) 26 (0.59) 15 (0.54) 14 (0.65)
Rosacea Acne
Model Odds ratio 95% CI P-value Model Odds ratio 95% CI P-value
Univariate 0.694 0.610–0.789 o0.0001 Univariate 0.792 0.619–1.015 0.0655
Multivariate 0.775 0.678–0.885 0.0002 Multivariate 1.156 0.882–1.515 0.2952
Abbreviation: CI, confidence interval.
Multivariate model adjusted for covariates including age, gender, and comorbidities (diabetes, dyslipidemia, and hypertension).
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end point was to detect new diagnoses
of cardiovascular disease, we felt that
these exclusion criteria were necessary
to calculate the incidence of disease.
Patient adherence cannot be assessed
from pharmacy records. Other medica-
tions, family history, or lifestyle vari-
ables were not included in our analysis.
All patients who were prescribed
a tetracycline, regardless of duration,
were included. It is not possible to know
whether the prescription was truly given
for acne/rosacea versus an infection.
There are data that rosacea itself may
increase the risk of cardiovascular dis-
ease (Duman et al., 2013), and it is
possible that any indication for a
tetracycline may perhaps positively
affect the pro-inflammatory state of the
rosacea patient.
In private practice, the use of low-dose
(20 or 40 mg daily) doxycycline is com-
monplace in order to take advantage of
the sub-antimicrobial dose that also pro-
vides an anti-inflammatory effect in rosa-
cea. This formulation is not available at
our facility, and most patients were pre-
scribed between 50–200 mg daily.
Owing to sampling issues (three differ-
ent medications in two different groups
of patients, acne, and rosacea), we did
not analyze the odds ratio for each of the
tetracycline medications: tetracycline,
doxycycline, and minocycline.
Finally, as our veteran population was
predominantly male, our results may not
be generalizable to a more heteroge-
neous population.
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TO THE EDITOR
Hereditary palmoplantar keratodermas
(PPKs) consist of a heterogeneous group
of hyperkeratotic disorders involving
mainly the palms and the soles (Lucker
et al., 1994). Nagashima-type palmo-
plantar keratosis (NPPK, MIM615598)
was initially described in Japanese
literature as a mild form of mal de
Meleda (MIM248300), which is one of
the diffuse autosomal-recessive PPKs
(Nagashima, 1977). Later, similar cases
were reported both in Japanese andAccepted article preview online 10 February 2014; published online 10 April 2014
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